BioMarin Bulls Are Counting on Gene Therapy to Reignite the Stock

(Bloomberg) -- One of biotechnology’s most closely watched stocks will face a crucial test over the next month when investors get a fresh look at data on its hemophilia A gene therapy.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.